- Previous Close
0.9501 - Open
1.0700 - Bid 0.9717 x 700
- Ask 1.0200 x 100
- Day's Range
0.9700 - 1.0800 - 52 Week Range
0.2400 - 2.6700 - Volume
2,246,007 - Avg. Volume
16,247,368 - Market Cap (intraday)
5.954M - Beta (5Y Monthly) 0.73
- PE Ratio (TTM)
-- - EPS (TTM)
-2.3700 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.38
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
plustherapeutics.comRecent News: PSTV
View More
Performance Overview: PSTV
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PSTV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PSTV
View MoreValuation Measures
Market Cap
5.66M
Enterprise Value
4.27M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-225.07%
Return on Assets (ttm)
-90.42%
Return on Equity (ttm)
--
Revenue (ttm)
5.72M
Net Income Avi to Common (ttm)
-12.88M
Diluted EPS (ttm)
-2.3700
Balance Sheet and Cash Flow
Total Cash (mrq)
4.79M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-8.11M
Research Analysis: PSTV
View MoreResearch Reports: PSTV
View MoreDaily – Vickers Top Insider Picks for 12/10/2024
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 12/09/2024
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 12/06/2024
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 12/05/2024
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.